Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. More Details
Outstanding track record with flawless balance sheet.
Share Price & News
How has Aarti Drugs's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AARTIDRUGS is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: AARTIDRUGS's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: AARTIDRUGS exceeded the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: AARTIDRUGS exceeded the Indian Market which returned 53% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Aarti Drugs's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Aarti Drugs Limited (NSE:AARTIDRUGS) Popular Amongst Insiders?
2 months ago | Simply Wall StIs Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value
2 months ago | Simply Wall StImagine Holding Aarti Drugs (NSE:AARTIDRUGS) Shares While The Price Zoomed 516% Higher
Is Aarti Drugs undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: AARTIDRUGS (₹717.15) is trading above our estimate of fair value (₹289.39)
Significantly Below Fair Value: AARTIDRUGS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AARTIDRUGS is good value based on its PE Ratio (23.8x) compared to the Indian Pharmaceuticals industry average (26x).
PE vs Market: AARTIDRUGS's PE Ratio (23.8x) is in line with the Indian market.
Price to Earnings Growth Ratio
PEG Ratio: AARTIDRUGS is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: AARTIDRUGS is overvalued based on its PB Ratio (7.3x) compared to the IN Pharmaceuticals industry average (3.4x).
How is Aarti Drugs forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AARTIDRUGS's forecast earnings growth (25.7% per year) is above the savings rate (6.8%).
Earnings vs Market: AARTIDRUGS's earnings (25.7% per year) are forecast to grow faster than the Indian market (21.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AARTIDRUGS's revenue (20% per year) is forecast to grow faster than the Indian market (12.6% per year).
High Growth Revenue: AARTIDRUGS's revenue (20% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AARTIDRUGS's Return on Equity is forecast to be high in 3 years time (32.2%)
How has Aarti Drugs performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AARTIDRUGS has high quality earnings.
Growing Profit Margin: AARTIDRUGS's current net profit margins (13%) are higher than last year (7.8%).
Past Earnings Growth Analysis
Earnings Trend: AARTIDRUGS's earnings have grown significantly by 30.5% per year over the past 5 years.
Accelerating Growth: AARTIDRUGS's earnings growth over the past year (98.3%) exceeds its 5-year average (30.5% per year).
Earnings vs Industry: AARTIDRUGS earnings growth over the past year (98.3%) exceeded the Pharmaceuticals industry 58.3%.
Return on Equity
High ROE: AARTIDRUGS's Return on Equity (30.7%) is considered high.
How is Aarti Drugs's financial position?
Financial Position Analysis
Short Term Liabilities: AARTIDRUGS's short term assets (₹10.6B) exceed its short term liabilities (₹6.0B).
Long Term Liabilities: AARTIDRUGS's short term assets (₹10.6B) exceed its long term liabilities (₹2.6B).
Debt to Equity History and Analysis
Debt Level: AARTIDRUGS's debt to equity ratio (32.3%) is considered satisfactory.
Reducing Debt: AARTIDRUGS's debt to equity ratio has reduced from 135.3% to 32.3% over the past 5 years.
Debt Coverage: AARTIDRUGS's debt is well covered by operating cash flow (52.4%).
Interest Coverage: AARTIDRUGS's interest payments on its debt are well covered by EBIT (16.9x coverage).
What is Aarti Drugs's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AARTIDRUGS's dividend (0.35%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.36%).
High Dividend: AARTIDRUGS's dividend (0.35%) is low compared to the top 25% of dividend payers in the Indian market (1.44%).
Stability and Growth of Payments
Stable Dividend: AARTIDRUGS's dividend payments have been volatile in the past 10 years.
Growing Dividend: AARTIDRUGS's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (8.3%), AARTIDRUGS's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: AARTIDRUGS's dividends in 3 years are forecast to be thoroughly covered by earnings (11.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Prakash Patil (74 yo)
Mr. Prakash Moreshwar Patil has been the Chairman of the Board of Aarti Drugs Limited since April 2014. Mr. Patil has been the Managing Director of Aarti Drugs Limited since June 1, 2007 and serves as its...
CEO Compensation Analysis
Compensation vs Market: Prakash's total compensation ($USD256.46K) is below average for companies of similar size in the Indian market ($USD387.57K).
Compensation vs Earnings: Prakash's compensation has increased by more than 20% in the past year.
Experienced Management: AARTIDRUGS's management team is seasoned and experienced (6.8 years average tenure).
Experienced Board: AARTIDRUGS's board of directors are seasoned and experienced ( 12.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AARTIDRUGS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Aarti Drugs Limited's company bio, employee growth, exchange listings and data sources
- Name: Aarti Drugs Limited
- Ticker: AARTIDRUGS
- Exchange: NSEI
- Founded: 1984
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹66.357b
- Shares outstanding: 92.60m
- Website: https://www.aartidrugs.co.in
Number of Employees
- Aarti Drugs Limited
- Mahendra Industrial Estate
- Ground Floor
- 400 022
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. It offers active pharmaceutical ingredients in various therapeutic categories, including...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/23 16:11|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.